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patients, implanted with a non-rechargeable device (Kinetra™, Soletra™, Itrel
®
2)
between 1996 and 2010. Overall, 117 implantations were performed (primo-implan-
tation and replacement). The mediane time to replacement of the non-recharge-
able devices was 2.9 years, ranging between 0.4 and 7.8 years. When extrapolated to
the cohort population, the use of the rechargeable device would have avoided a
total number of 215 hospitalizations over 9 years. The number of days of hospital-
ization avoided per patient was 10 days. The direct medical cost (device and hos-
pitalization tariffs) avoided per patient was 27 886€. CONCLUSIONS: Over 9 years,
the rechargeable DBS device allows to avoid 2 device replacements per patient.
This is associated with a 40 % reduction of the total number of days in hospital, and
43% reduction in the direct medical cost. The rechargeable neurostimulator
Activa
®
RC is adapted to patients with high energy needs like dystonia patients,
with a time to replacement of 5 years or less.
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OBJECTIVES: PRECISE study aims to assess the costs and the clinical benefits of
Spinal Cord Stimulation (SCS) (plus conventional medical management, CMM) in
the treatment of Failed Back Surgery Syndrome (FBSS) patients not adequately
responding to CMM alone. Being the study closed, we report the preliminary clin-
ical and resource consumption final results.METHODS:An observational, pre-post
data collection with a 24-months follow-up (FU) was developed in 9 Italian Hospi-
tals. Resource consumption, clinical outcomes (Pain Numerical Rating Scale - NRS,
Oswestry Disability Index - ODI) and HR-QoL data (SF-36, EQ-5D) were collected
before and after the SCS system implantation in order to be compared. RESULTS:
Fifty-five of the 72 patients implanted (out of the 80 enrolled for the SCS screening)
completed the study. Seventeen discontinued the therapy due to: consent with-
drawal (24%), loss to FU (24%), SCS-related issues (29%), non-SCS related reasons
(24%). Mean pain intensity decreased from 7.41.4 to 4.22.6 in the first 12 months,
remaining consistent through the second year of FU (4.12.5). A continuous im-
provement in function measured with ODI was appreciated: 47 (85%) patients im-
proved in the first year and 33 (60%) during the second, for a total of 41 (82%)
patients improved at 24-month FU if compared to the baseline. EQ-VAS increased
from 37 to 60 (12-months) to 63 (24-months). All SF-36 domains significantly im-
proved, and especially “Bodily Pain”, “Social Functioning”, “Role Emotional”. With
respect to the baseline, the monthly per-patient resource consumption decreased:
considering the second year of follow-up, both pain-related hospitalizations and
GP visits experienced a 70% reduction in number, diagnostic exams diminished by
the 82%. Monthly caregivers’ days off from work dropped by the 80% (from 45 to 9).
CONCLUSIONS: SCS allows a better and sustained pain control and HR-QoL im-
provement. If compared with CMM alone, SCS permits a reduction in resource
consumption and productivity losses.
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OBJECTIVES:Diagnosis of patients with dyspnea and suspected acute heart failure
(HF) using NT-proBNP testing has been studied internationally. We aimed to ana-
lyze the efficiency of NT-proBNP compared to standard clinical evaluation alone
use in Spanish Emergency Departments. METHODS: A decision-analytic model
was developed to evaluate the clinical and economic outcomes of both diagnostic
alternatives. Model’s time horizon started at patient ED visits and ended after 60
days of follow-up (taking into account differences between hospitalized and non-
hospitalized patients). Clinical parameters were mainly extracted from the PRIDE
study and were validated by expert opinion (ED and cardiology doctors). We as-
sumed that 65% of patients with dyspnea had HF based on Spanish published data.
Resource use was obtained through expert opinion and examined under a National
Healthcare System (NHS) perspective. We considered a 900 pg/ml cut-point for
NT-proBNP test (sensitivity of 90% and specificity of 85%). Our model compared
final diagnostic result with the initial diagnostic before ED discharge. A probabilis-
tic sensitivity analysis was carried out in order to handle uncertainty. RESULTS:
Diagnosis using NT-proBNP testing was correct in 91.96% of patients (59.09% true
positive cases and 32.87% true negative cases) versus 85.53% with the standard
clinical evaluation alone (50.79% of true positive cases and 34.74% of true negative
cases). Besides, NT-proBNP testing involved less costs (4,045€ versus 5,405€) mainly
due to less hospitalizations and a shorter length of stay. Robustness of results was
confirmed through a sensitivity analysis. CONCLUSIONS: NT-proBNP test is less
costly per correctly diagnosed patient than standard clinical evaluation alone in
the assessment and management of patients with dyspnea at ED rooms from Span-
ish NHS perspective.
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OBJECTIVES: Liver imaging techniques aim to correctly characterize focal lesions
and influence choices of therapeutic strategies. The objective of this study was to
compare diagnostic efficacy and direct medical costs of contrast-enhanced ultra-
sound (CEUS) to magnetic resonance imaging (MRI) or computed tomography (CT)
in the characterization of focal liver lesions in the The Netherlands. METHODS:
This prospective study enrolled 170 patients at an academic hospital in the The
Netherlands. A decision model was designed to compare two diagnostic algorithms
based on the results of the study: 1) a typical patient work-up, which included
ultrasound (US), followed by an MRI or CT examination, and 2) a new patient
work-up in which CEUS was performed after US. The perspective of the healthcare
sector in the The Netherlands was used. Clinical outcomes were ‘correctly charac-
terizedx benign and malignant liver lesions and life-years (LY). Model inputs were
taken from the hospital database, literature and publicly available sources. Time
horizon was two years. One-way and probabilistic sensitivity analyses were per-
formed to assess uncertainty in the results. RESULTS: CEUS was able to identify
benign and malignant focal liver lesions with a sensitivity of 96.9% and specificity
of 92.3%. For correct tumor subgroup characterization, sensitivity and specificity
were 86.2% and 85.6% respectively. Base-case results revealed that the CEUS strat-
egy had similar effectiveness compared to the MRI/CT strategy (incremental effects
of 0.002 LYs) and resulted in cost-savings of €452. The cost-savings for diagnostic
phase and treatment phase were €160 and €292 respectively. The results were
sensitive to specificity, sensitivity and cost of the diagnostic tests. Robustness of
the results was confirmed by probabilistic sensitivity analysis. CONCLUSIONS:
This study demonstrates that CEUS is a cost-saving alternative compared to the
traditional diagnostic procedures and should be considered as one of the ‘first
stepx options in the front-line characterization of focal liver lesions in the The
Netherlands.
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OBJECTIVES: The treatment of chronic lymphoedema (CL) is of particular health
economic interest since, due to its chronic nature and continuous need for treat-
ment, it is associated with high costs and considerable patient burden. The objec-
tive of this study was to assess the cost-effectiveness of 3M™ Coban 2™ compres-
sion system in the treatment of CL compared to Comprilan® short-stretch bandage
compression therapy. METHODS: In the UK and the United States a multi-center,
prospective, open-label study was conducted, including patients with CL of the legs
(n40) and the arms (n42). Patients were randomly assigned to the four treatment
arms (3M™ Coban 2™ compression treatment either daily, 2x/wk or 3x/wk, and
daily compression therapy with Comprilan® bandages). Cost analysis from the UK
payors’ perspective was based on material costs and personal resource utilization
for bandage changes and for manual lymphtherapy. Clinical outcomes in the cost-
effectiveness analysis was defined as mean volume reduction at the end of therapy
(19 days). RESULTS: On average, 3 weeks treatment for a patient with lymphoe-
dema added to 1,297.96 € for the health service comissioners and up to 576,54 € for
the physiotherapists across all groups. Lymphoedema treatment with 3M™ Coban
2™ compression system twice a week was more cost-effective than the other treat-
ments (ICER 37.65 € per % reduction of circumference vs. 146.60 € (daily), 145.67 €
(3x/wk) and 147.53 € (daily compression therapy with Comprilan® bandages)). Re-
sults were comparable for patients with CL of the upper and lower extremities,
respecitvely. Sensitivity analysis provided stable results after variation of costs,
utilization rates and clinical outcomes. CONCLUSIONS: Treatment of lymphoe-
dema with 3M™ Coban 2™ compression system twice a week is more efficient than
treatments applied daily or three times per week.
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OBJECTIVES: Transcatheter aortic valve implantation (TAVI) represents an inno-
vative technology superior to medical management (PARTNER study, US) in inop-
erable patients with severe aortic valve stenosis (AVS). This study aims to estimate
the cost-effectiveness of TAVI compared to conservative medical management in
symptomatic AVS patients in Spain. METHODS: A economic longitudinal cohort
model was used to predict clinical and economic outcomes of symptomatic AVS
patients treated with either transapical (TA) or transfemoral (TF) TAVI, or medical
management alone (MEDICAL). Clinical model input data for TAVI was derived
from the real-world SOURCE registry, and for MEDICAL from literature and a reg-
istry of 60 untreated Spanish AVS patients followed up for 336 days. Health utilities
as well as resource use and unit costs utilized for modelling are representative for
Spain. Missing information was substituted by expert estimates. Economic results
A248 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
